Clinical trial
Open access
Sep 2026
Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer
Biweekly gemcitabine plus nab‐paclitaxel plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains limited.
K. Ikezawa, T. Imai, R. Takada et al.
· Cancer Reports · 0 citations